Insider sales are small in absolute terms (0.075% of market cap) and occur after option exercises—indicative of post-vesting profit-taking rather than a bearish conviction signal. The cluster is amplified by recent dilutive offerings but does not independently suggest material adverse information. Monitor for any pre-announcement of AMT-130 BLA timing or trial data; upcoming Q3 2026 filing is the primary catalyst.
Price Chart
Executive Summary
Cluster of insider sales at uniQure following two recent $225M and $150M capital raises, with total open-market insider sales of ~$2.1M (0.075% of $2.8B market cap). Director Kaye Jack and CMO Abi-Saab Walid sold shares on June 30 after exercising low-strike options, and CEO Matthew Kapusta sold $1.44M on June 25. The sales are small relative to market cap but the timing—immediately after dilutive offerings and ahead of a pivotal BLA filing—raises optics concerns.
Key Financial Metrics
Key Facts
- Open-market insider sales total ~$2.09M across three insiders within 7 days.
- CEO Matthew Kapusta sold $1.44M worth of shares on June 25 at ~$50.02.
- Director Kaye Jack sold ~$1.0M total on June 30, with offsetting derivative exercises at $0-$20.18 strikes.
- CMO Walid Abi-Saab sold $1.39M total on June 30, including exercises of low-strike options.
- These sales follow a $225M public offering priced on June 23 at $45.50 (7.2% discount) and a $150M offering announced June 22.
- Offering proceeds are earmarked for AMT-130 (Huntington's gene therapy) BLA filing and commercialization.
- Total insider sales represent ~0.075% of market cap, below the 0.1% threshold for materiality.
- Non-cash derivative exercises on June 30 account for $552K in shares received at zero or low cost, all sold same-day.
- No 10b5-1 plan indicated; timing aligns with post-offering blackout window reopening.
Financial Impact
Total insider open-market sales of ~$2.09M (0.075% of market cap), combined with $375M in recent dilutive offerings that added ~7.8% share count dilution.
Risk Factors
- Insiders selling after option exercises could signal limited conviction in near-term stock upside post-offering dilution.
- CEO sale of $1.44M at $50 (above offering price of $45.50) may be purely liquidity-driven but timing is unfavorable.
- Concentration of sales on June 30—the same day for Kaye and Abi-Saab—suggests a shared blackout window reopening.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1783060238191 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access